Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06831552 · ClinicalTrials.gov registry record · NA
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
A NA study of Neuroblastoma and High-risk Neuroblastoma, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 84
- Enrollment target
- 6
- Study locations
NCT06831552: Recruiting NA study of Neuroblastoma and High-risk Neuroblastoma, sponsored by Dana-Farber Cancer Institute.
NCT06831552 is a NA study of Neuroblastoma and High-risk Neuroblastoma that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 84 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (65% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06831552, a NA study of Neuroblastoma and High-risk Neuroblastoma, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 84 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity \[Pediatric RISE\]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centered outcomes. Participants will be randomized to receive one of the following for 6-months: * Usual supportive care alone or * Usual supportive care plus Pediatric RISE
Primary Outcome
HMH score reduction rate is defined as the proportion of patients achieving at least 1 domain reduction in (food, housing, utility or transportation insecurity). HMH scores range from 0 to 4, with scores of 0 indicating no hardship (unexposed) and scores of 1-4 indicating the presence of hardship (exposed). Patients who are unexposed to HMH at baseline (HMH score of 0) are excluded from the analysis.
Conditions Studied
Interventions
- BEHAVIORAL RISE Intervention
Study Locations (6)
Connecticut
- Connecticut Children's Medical Center - Hartford
Georgia
- Children's Healthcare of Atlanta - Atlanta
Massachusetts
- Dana-Farber Cancer Institute - Boston
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- University of Texas Southwestern Medical Center - Dallas
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2025-04-30 |
| Est. Completion | 2029-06-01 |
| Phase | NA |
What NCT06831552 shows while recruiting
NCT06831552 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which RISE Intervention is the first listed.
NCT06831552 lists 6 locations in 6 states (Connecticut, Georgia, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06831552 about?
NCT06831552 is a clinical study titled "Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma". The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity \[Pediatric RISE\]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centere...
What is the current status of trial NCT06831552?
This trial is currently recruiting. It is a NA study. The enrollment target is 84 participants. The study started on 2025-04-30. Estimated completion is 2029-06-01.
What conditions does trial NCT06831552 study?
This clinical trial studies the following conditions: Neuroblastoma, High-risk Neuroblastoma.
What interventions are being tested in trial NCT06831552?
The interventions under investigation include: RISE Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT06831552?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06831552 being conducted?
This trial has 6 study locations across Connecticut, Georgia, Massachusetts, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06831552's enrollment target sits among peer trials
84 37th of 94 higher than 58 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCT for the Harvard/UCSF ROBIN Center
RECRUITING · NA
-
Phase II Study of Proton Radiation Therapy for Neuroblastoma
RECRUITING · NA
-
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study
ACTIVE NOT RECRUITING · NA
-
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
COMPLETED · NA
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI